Utilization and expense of adjuvant cancer therapies following radical prostatectomy

Cancer

Volumn 117, Issue 21, 2011, Pages 4846-4854

  Williams, Stephen B ^a   Gu, Xiangmei ^a   Lipsitz, Stuart R ^a   Nguyen, Paul L ^b   Choueiri, Toni K ^b   Hu, Jim C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

adjuvant therapy; expenditures; outcomes; prostatectomy; utilization

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SIZE; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; ETHNICITY; GEOGRAPHIC DISTRIBUTION; GLEASON SCORE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURGICAL APPROACH;

AGED; COMBINED MODALITY THERAPY; HORMONES; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 80054819859     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26012     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004; 171: 1393-1401. (Pubitemid 38365382)
3. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006; 24: 3973-3978. (Pubitemid 46630746)
4. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299: 2760-2769. (Pubitemid 351846851)
5. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181: 956-962.
6. Choueiri TK, Chen MH, D'Amico AV, et al. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010; 116: 1887-1892.
7. Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 11: 450-458.
8. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010; 121: 833-840.
9. Skolarus TA, Zhang Y, Miller DC, et al. The economic burden of prostate cancer survivorship care. J Urol. 2010; 184: 532-538.
10. Agarwal PK, Sadetsky N, Konety BR, et al. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008; 112: 307-314.
11. Konety BR, Cowan JE, Carroll PR,. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008; 179: 1797-1803; discussion 1803.
12. Lu-Yao GL, Potosky AL, Albertsen PC, et al. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996; 88: 166-173. (Pubitemid 26065828)
13. Cooperberg MR, Moul JW, Carroll PR,. The changing face of prostate cancer. J Clin Oncol. 2005; 23: 8146-8151. (Pubitemid 46211547)
14. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40: IV-3-18.
15. Tewari AK, Jhaveri JK, Surasi K, et al. Benefit of robotic assistance in comparing outcomes of minimally invasive versus open radical prostatectomy. J Clin Oncol. 2008; 26: 4999-5000; author reply 5001-5002.
16. Hu JC, Wang Q, Pashos CL, et al. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol. 2008; 26: 2278-2284.
17. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007; 177: 540-545. (Pubitemid 46054056)
18. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267. (Pubitemid 32007842)
19. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974. (Pubitemid 28445094)
20. Hu JC, Gold KF, Pashos CL, et al. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol. 2003; 21: 401-405. (Pubitemid 46606466)
21. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002; 346: 1138-1144. (Pubitemid 34984605)
22. Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Fund. Washington, DC; 2008.
23. Rao JNK, Scott AJ,. The analysis of categorical data from complex surveys: chi-squared tests for goodness of fit and independence in two-way tables. J Am Stat Assoc. 1981; 76: 221-230.
24. Swindle P, Eastham JA, Ohori M, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 2005; 174: 903-907. (Pubitemid 41140626)
25. Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001; 165: 119-125.
26. Mehta SS, Lubeck DP, Sadetsky N, et al. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol. 2004; 171: 215-219. (Pubitemid 37549126)
27. Grossfeld GD, Stier DM, Flanders SC, et al. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol. 1998; 160: 1398-1404. (Pubitemid 29480525)
28. Bianco FJ Jr, Vickers AJ, Cronin AM, et al. Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol. 2010; 183: 977-982.
29. Moreira DM, Banez LL, Presti JC Jr, et al. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2010; 105: 28-33.
30. Stamey TA, McNeal JE, Yemoto CM, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999; 281: 1395-1400. (Pubitemid 29190217)
31. Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007; 25: 4178-4186. (Pubitemid 47548556)
32. Thompson IM, Tangen CM, Klein EA,. Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol. 2009; 27: 2898-2899.
33. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341: 1781-1788.
34. Da Pozzo LF, Cozzarini C, Briganti A, et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol. 2009; 55: 1003-1011.
35. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009; 302: 1557-1564.
36. Wieder JA, Soloway MS,. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol. 1998; 160: 299-315. (Pubitemid 29476668)
37. Cheng L, Slezak J, Bergstralh EJ, et al. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol. 2000; 18: 2862-2868. (Pubitemid 30620074)
38. Patel AA, Chen MH, Renshaw AA, et al. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA. 2007; 298: 1533-1538. (Pubitemid 47529387)
39. D'Amico AV, Wu Y, Chen MH, et al. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol. 2001; 165: 126-129.